Renovaro Inc., a leader in TechBio specializing in diagnostics, drug discovery, and cancer therapies, has announced an expedited trial date in its lawsuit against Predictive Oncology Inc. The litigation, filed on May 9, 2025, in the Delaware Court of Chancery, seeks to enforce a binding merger agreement initially executed on January 1, 2025. Renovaro alleges that Predictive Oncology breached provisions of the agreement by conducting a public offering of $545,000 in securities and attempting to terminate the agreement unilaterally without meaningful negotiations. Renovaro is pursuing specific performance, injunctive relief, and damages, with the case currently pending under Case No. 2025-0509.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。